Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
8.87
+0.10 (1.14%)
At close: Apr 2, 2026, 4:00 PM EDT
9.04
+0.17 (1.92%)
After-hours: Apr 2, 2026, 6:32 PM EDT
Kyverna Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
129
Market Cap
536.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 7.03M | 1.37M | 24.20% |
| Dec 31, 2021 | 5.66M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CorMedix | 311.71M |
| Rigel Pharmaceuticals | 294.28M |
| Zevra Therapeutics | 106.47M |
| 4D Molecular Therapeutics | 85.21M |
| Prothena Corporation | 9.68M |
| Upstream Bio | 2.85M |
| ProKidney | 893.00K |
| YD Bio | 510.36K |
KYTX News
- 7 days ago - Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 20 days ago - Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 4 weeks ago - Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026 - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics to Participate in Upcoming March Investor Conferences - GlobeNewsWire
- 4 weeks ago - Kyverna Therapeutics: The King Of The CAR-T Autoimmune Revolution - Seeking Alpha
- 5 weeks ago - Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of Directors - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer - GlobeNewsWire
- 2 months ago - Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference - GlobeNewsWire